Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

524
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
524
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

264
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
264
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

95
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
95
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

130
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
130
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

115
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
115
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

137
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
137

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tailoring Antiplatelet Therapy Duration After PFO Closure: Insights From the PROLONG Registry.

JACC. Advances·2026
Same author

Inhibition of late sodium current (INa) to prevent coronary MICROvascular dysfunction in patients presenting with ST-elevation myocardial infarction and multivessel disease: A phase IIb multicenter, randomized, controlled and open label study (INaMICRON).

International journal of cardiology·2026
Same author

Use of cangrelor in patients with reduced renal function: Post-hoc analysis from the ARCANGELO study.

International journal of cardiology·2026
Same author

Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry.

Journal of clinical medicine·2026
Same author

SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

A leap into the future: excluding the ischaemic origin of chest pain through artificial intelligence.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Double Transseptal Guide Sheath Technique to Prevent Low Dock Positioning During Transcatheter Mitral Valve Replacement.

JACC. Cardiovascular interventions·2026
Same journal

Real-World Outcomes of Dedicated Leaflet Modification for Bioprosthetic Valve-In-Valve TAVR: A 150-Patient Commercial Experience.

JACC. Cardiovascular interventions·2026
Same journal

Effect of Nominal-Volume ("Double Tap") Postdilatation on Significant THV Mid-Stent Frame Underexpansion After Balloon-Expandable TAVR.

JACC. Cardiovascular interventions·2026
Same journal

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same journal

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same journal

REPLY: The Angiographic Veto: Putting the Operator Back in DAPT De-Escalation.

JACC. Cardiovascular interventions·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K

Do We Really Need Routine CYP2C19 Genotyping?

Simone Calcagno, Riccardo Di Pietro, Giuseppe Biondi-Zoccai

    JACC. Cardiovascular Interventions
    |May 9, 2020
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
    07:24

    Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

    Published on: February 10, 2023

    1.8K
    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    19.0K

    Related Experiment Videos

    Last Updated: Dec 22, 2025

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
    07:00

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

    Published on: April 1, 2019

    10.3K
    Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
    07:24

    Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

    Published on: February 10, 2023

    1.8K
    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    19.0K